KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2025)

Vir Biotechnology's Accumulated Expenses history spans 7 years, with the latest figure at $83.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 15.74% year-over-year to $83.0 million; the TTM value through Dec 2025 reached $83.0 million, down 15.74%, while the annual FY2025 figure was $83.0 million, 15.74% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $83.0 million at Vir Biotechnology, roughly flat from $82.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $489.1 million in Q4 2022 and bottomed at $7.7 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $90.8 million (2024), against an average of $134.6 million.
  • The largest annual shift saw Accumulated Expenses crashed 81.8% in 2021 before it skyrocketed 733.6% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $58.7 million in 2021, then surged by 733.6% to $489.1 million in 2022, then crashed by 78.69% to $104.2 million in 2023, then dropped by 5.47% to $98.5 million in 2024, then dropped by 15.74% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Accumulated Expenses are $83.0 million (Q4 2025), $82.7 million (Q2 2025), and $104.1 million (Q1 2025).